353
Participants
Start Date
January 14, 2021
Primary Completion Date
August 24, 2021
Study Completion Date
August 24, 2021
REGN5713
Administered subcutaneously
REGN5714
Administered subcutaneously
REGN5715
Administered subcutaneously
Placebo
Placebo that replaces REGN5713-5714-5715
Regeneron Study Site, Hvidovre
Regeneron Study Site, Hellerup
Regeneron Study Site, Leuven
Regeneron Study Site, Vejle
Regeneron Study Site, Ghent
Regeneron Study Site, Berlin
Regeneron Study Site, Great Neck
Regeneron Study Site, Berlin
Regeneron Study Site, Pittsburgh
Regeneron Study Site, Baltimore
Regeneron Study Site, Hamburg
Regeneron Study Site, Düsseldorf
Regeneron Study Site, Toledo
Regeneron Study Site, Cincinnati
Regeneron Study Site, Duisburg
Regeneron Study Site, Greenfield
Regeneron Study Site, Plymouth
Regeneron Study Site, Missoula
Regeneron Study Site, St Louis
Regeneron Study Site, Dreieich
Regeneron Study Site, Wiesbaden
Regeneron Study Site, Columbia
Regeneron Study Site, Heidelberg
Regeneron Study Site, Stuttgart
Regeneron Study Site, Portland
Regeneron Study Site, Bangor
Regeneron Study Site, Verona
Regeneron Study Site, Lincoln
Regeneron Study Site, Kingston
Regeneron Study Site, London
Regeneron Study Site, Ottawa
Regeneron Study Site, Toronto
Regeneron Study Site, Toronto
Regeneron Study Site, Toronto
Regeneron Study Site, Trois-Rivières
Regeneron Study Site, Québec
Regeneron Study Site, Dresden
Regeneron Pharmaceuticals
INDUSTRY